Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Test entities : Eli lilly and company save search
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: 1.06%
H: 0.47%
C: -0.03%
fda device disease test granted blood designation for alzheimer's roche
Kidney Function Test Market to Earn Massive Revenue by 2029 | Brandessence Market Research
Published: 2023-09-18 (Crawled : 08:00) - prnewswire.com
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: -2.38%
H: 0.0%
C: -1.16%
BAX | $40.825 -0.48% 1M
|
Health Technology
|
| O: -0.13%
H: 0.28%
C: -0.77%
test kidney research market
Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic
Published: 2022-06-28 (Crawled : 12:20) - globenewswire.com
AKYA | News | $3.83 0.53% 58K
|
Professional, Scientific, and T...
|
| O: 1.0%
H: 4.77%
C: 3.37%
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
oncosignature test diagnostic therapeutics
Tempus Announces Sequencing Collaboration With Lilly to Expand Access to Genomic Testing
Published: 2022-06-09 (Crawled : 15:20) - biospace.com/
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: -0.6%
H: 0.1%
C: -2.68%
collaboration genomic test
NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay
Published: 2022-04-25 (Crawled : 12:00) - biospace.com/
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: -3.29%
H: 2.58%
C: 2.31%
NEO | $13.92 -1.7% 270K
|
Health Services
|
| O: -2.83%
H: 2.64%
C: 2.27%
partnership program cancer test
Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed By A Validated Diagnostic Test That Have Progressed After at Least One Prior Line of Systemic Therapy
Published: 2022-04-06 (Crawled : 05:00) - prnewswire.com
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: 1.23%
H: 3.54%
C: 3.29%
INCY | $51.45 -0.39% 720K
|
Health Technology
|
| O: -0.47%
H: 2.2%
C: 1.93%
pemazyre treatment test diagnostic approval one therapy
Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
ford test injection insulin
Oncomine Dx Target Test Receives MHLW Approval as a Companion Diagnostic for Eli Lilly's RET-Inhibitor in Non-Small Cell Lung Cancer in Japan
Published: 2021-09-10 (Crawled : 12:15) - prnewswire.com
TMO | News | $576.13 0.27% 1.1M
|
Health Technology
|
| O: 0.49%
H: 0.71%
C: 0.07%
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: 0.92%
H: 0.7%
C: -1.11%
lung cancer test cancer approval diagnostic
Latest Data From SURPASS Trials Demonstrate Tirzepatide Provided Meaningful Blood Sugar Reductions And Weight Loss
Published: 2021-06-29 (Crawled : 17:00) - biospace.com/
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: 0.01%
H: 1.38%
C: 0.49%
weight loss blood test trial tirzepatide
$10+ Billion Blood Glucose Monitoring Devices Global Market to 2026 - Increasing Awareness About Point of Care Testing Presents Opportunities
Published: 2021-06-17 (Crawled : 21:00) - prnewswire.com
MDT | $80.37 -1.13% 2.6M
|
Health Technology
|
| O: -1.29%
H: 0.62%
C: -0.29%
JNJ | News | $148.66 -0.6% 5.2M
|
Health Technology
|
| O: -1.18%
H: 0.56%
C: -0.79%
FMC A | $58.3 -0.6% 550K
|
Process Industries
|
| O: -1.33%
H: 0.4%
C: -3.77%
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: -0.8%
H: 0.28%
C: -0.85%
ABT | News | $106.74 -0.79% 3.3M
|
Health Technology
|
| O: -1.46%
H: 1.23%
C: 0.3%
SNY | News | $46.765 -1.94% 950K
|
Health Technology
|
| O: -1.9%
H: 1.38%
C: 1.21%
DXCM | $137.13 2.34% 1.7M
|
Health Technology
|
| O: -0.13%
H: 1.77%
C: 1.55%
blood test device
First Phase Results of MYLUNG Consortium Provide Historical View of Biomarker Testing Patterns and Identify Data Gaps for Ongoing Prospective Research
Published: 2021-06-04 (Crawled : 20:00) - biospace.com/
MCK | $535.46 0.65% 190K
|
Distribution Services
|
| O: 0.27%
H: 0.48%
C: 0.29%
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: 0.04%
H: 0.82%
C: -0.38%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 3.38%
H: 1.58%
C: -0.87%
ongoing test results research biomarkers
Psychedelics Move to The Forefront of Innovative Research as the FDA Approves Large-Scale Testing
Published: 2021-05-13 (Crawled : 13:00) - prnewswire.com
MRK | $127.33 0.36% 2.9M
|
Health Technology
|
| O: -0.14%
H: 1.41%
C: 1.03%
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: -0.49%
H: 2.01%
C: 1.4%
CMPS | $7.915 -4.06% 660K
|
Health Technology
|
| O: 4.4%
H: 0.0%
C: -10.26%
fda test research fda approval approval
Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting
Published: 2021-04-11 (Crawled : 20:20) - prnewswire.com
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.88%
test positive cancer gastrointestinal research
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3831 151.54% 190M
|
Consumer Services
CZOO | $11.04 121.24% 11M
|
BOF | $1.87 59.83% 100M
|
AMST | $3.18 59.0% 67M
|
Technology Services
LICN | $0.85 51.79% 13M
|
WIMI | $1.04 43.37% 17M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
MULN | News | $3.805 39.38% 11M
|
Information
RILY | $30.01 38.17% 11M
|
Finance
MTC | $3.04 35.71% 6.7M
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.